Key Takeaway: SL Science Holding Limited has reported its full year 2025 financial results, highlighting progress in its Gamma Delta T Cell and CD-19 Armed-T therapy platforms. The company is focused on expanding its oncology pipeline and enhancing its clinical development capabilities. Additionally, SL Science aims to accelerate its global growth following its recent Nasdaq listing.
Price reaction · baseline $5.79 (2026-06-18 close) · clean, no other SLBT news in the window
day 0 close
-21.9%
day 1 · peak
-31.6%
day 3
-27.6%
Market Sentiment Analysis
POSITIVE FACTORS
Advancement of Gamma Delta T Cell and CD-19 Armed-T therapy platforms.
Expansion of oncology pipeline and strengthening of clinical development.
Acceleration of global growth following Nasdaq listing.
Full Press Release Details
SL Science reported its full year 2025 financial results while advancing its Gamma Delta T Cell and CD-19 Armed-T therapy platforms. The company continues to expand its oncology pipeline, strengthen clinical development capabilities, and accelerate global growth following its Nasdaq listing.
Frequently Asked Questions
What financial results did SL Science report?
SL Science reported its full year 2025 financial results.
What therapy platforms is SL Science advancing?
The company is advancing its Gamma Delta T Cell and CD-19 Armed-T therapy platforms.
How is SL Science expanding its operations?
SL Science is expanding its oncology pipeline and strengthening clinical development capabilities.
What recent milestone did SL Science achieve?
SL Science is accelerating global growth following its Nasdaq listing.